Yukinori Okada
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (17)
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Identifying the causal variants and mechanisms that drive complex traits and diseases remains a core problem in human genetics 1–5 . Most of these variants individually have weak effects 6 and lie in non-coding gene-regulatory elements 7–10 , for which we lack a complete understanding of how single-nucleotide alterations modulate transcriptional processes to affect human phenotypes 5,11–15 . To address this problem, we measured the activity of 221,412 fine-mapped trait-associated variants using a massively parallel reporter assay 16–20 in 5 diverse cell types. We show that this assay effectively discriminates between likely causal variants and controls, and identified 13,121 regulatory variants with high precision. Although the effects of these variants largely agree with orthogonal measures of function, only 69% of them can plausibly be explained by the disruption of a known transcription factor binding motif. We investigated the mechanisms of 136 variants using saturation mutagenesis and assigned affected transcription factors for 91% of variants without a clear canonical mechanism. Finally, we detected regulatory epistasis at 11% of tested regulatory variants in close proximity and identified multiple functional variants on the same haplotype at a small, but important, subset of trait-associated loci. Overall, our study provides a systematic functional characterization of likely causal common variants that underlie complex and molecular human traits, enabling new insights into the regulatory grammar underlying disease risk.
Year:
2026
Background Sex hormone alterations, such as estrogen deficiency or testosterone excess, substantially increase cardiovascular disease (CVD) risk in females. Dietary fibre and its microbial by-products, short-chain fatty acids (SCFAs), have cardioprotective effects, but it remains unclear whether these benefits extend to females with an altered sex hormone profile. In this study, we aim to investigate whether dietary fibre intake, measured via plasma acetate—the most abundant SCFA—is associated with improved cardiovascular outcomes in females with altered sex hormone profiles. Methods This cohort study included 116,235 female participants from the UK Biobank and Biobank Japan with up to 10 years of follow-up. We analysed early menopause (as a surrogate for estrogen insufficiency) and plasma free testosterone (in a subset). The primary outcome was major adverse cardiovascular events (MACE). Secondary outcomes were blood pressure. Proteomics analyses explored potential mechanisms. Results Acetate levels were associated with lower 10-year MACE incidence (-0.618/1000 woman-year, HR=0.900, p=0.002) and systolic blood pressure (-0.231 mmHg per 1 SD, p <0.001) in the UK Biobank. High acetate levels attenuated the increased MACE risk associated with early menopause (HR=1.158, p =0.057) compared with low acetate (HR=1.425, p <0.001), with similar patterns replicated in Biobank Japan (high: HR=1.322, p =0.090; low: HR=1.385, p =0.042). Proteomics analyses suggested a mechanism involving pro-inflammatory proteins. Moreover, high acetate levels attenuated the increased MACE associated with elevated free testosterone in the UK Biobank (high: HR=1.238, p =0.024; low: HR=1.056, p =0.666). A significant interaction between acetate and free testosterone on systolic blood pressure indicated that the effect of rising testosterone on blunting acetate’s effect (β=0.167, 95% CI: [5.212×10⁻ 2 −2.818×10⁻ 1 ], p =0.004) was partially mediated by central obesity (waist-to-hip ratio). Conclusions Higher plasma acetate levels were associated with lower cardiovascular risk, particularly in females with early menopause or elevated free testosterone, potentially via inflammatory pathways. These findings underscore the importance of hormonal context in shaping cardiometabolic resilience and support personalised CVD prevention strategies for females with altered sex hormone profiles, including increasing dietary fibre intake.
Year:
2026
Many non-coding variants influence complex traits and diseases through gene regulation, yet the mechanisms linking these variants to downstream biology remain poorly understood. Here, we present eQTLGen Phase 2 , a comprehensive genome-wide analysis of gene expression quantitative trait loci (eQTLs) in 43,301 blood samples from 52 datasets. Beyond local cis -effects, this sample size enabled the first systematic mapping of trans -eQTLs at scale. We identify cis -eQTLs for nearly all expressed genes (94.7%) and trans -eQTLs for over half (56.2%). Second, by colocalizing cis -eQTLs with trans -eQTLs, we infer a directed gene regulatory network comprising 47,554 directed gene regulatory relationships. These networks reveal how genetic perturbations in upstream regulators produce dose-dependent downstream effects, supported by Perturb-seq and ChIP-seq data. Third, integrating this network with 87 genome-wide association studies allows us to systematically prioritize trait-relevant pathways and candidate genes. Variants exerting both cis – and trans -effects are markedly more likely to colocalize with trait associations than cis -only variants, delineating a subset of functionally active cis -eQTLs from a large group with limited downstream impact. This distinction provides a conceptual framework for identifying regulatory variants that truly mediate complex trait biology. Together, these results provide a publicly available resource of cis – and trans -eQTLs and an in vivo scaffold for human gene-regulatory networks, elucidating how propagation of cis -effects modulates complex disease.
Year:
2026
We report the findings of a genome-wide association study (GWAS) meta-analysis of endometriosis across 14 biobanks worldwide, including 32% non-European patient participants, as part of the Global Biobank Meta-Analysis Initiative (GBMI). Out of 58 total loci (29 previously unreported), the largest meta-analysis accounted for 46 (20 previously unreported). We detected the first genome-wide significant loci (2p13.3 and 20q13.2) uniquely driven by the African-ancestry meta-analysis. Our imaging- and surgery-confirmed phenotypes yielded six additional previously unreported loci. Leveraging our large and diverse study population, we observed SNP heritability estimates of 9-13% for all ancestry groups, and 13 loci had at least one variant in the credible set after fine-mapping. Investigating the complex array of endometriosis comorbidities and risk factors revealed 135 genetically correlated phenotypes and 95 with evidence of vertical pleiotropy, including triglycerides and anxiety disorders. We prioritized 35 disease-relevant cellular contexts from the endometrial cell atlas and found 322 examples of differentially expressed genes in cells from donors with endometriosis. Further high-throughput multi-omic analyses implicated a total of 282 genes in endometriosis pathogenesis. Our diverse, comprehensive GWASs, with downstream analyses spanning molecular to phenotypic scales, provide detailed evidence for aspects of endometriosis including the role of immune cell types, Wnt signaling, and cellular proliferation. These interconnected pathways and risk factors underscore the complex, multi-faceted etiology of endometriosis, suggesting multiple targets for precise and effective therapeutic interventions.
Year:
2025
Centromeres are among the most diverse and dynamically evolving regions of the human genome and are commonly affected in various human cancers. However, organized into highly repetitive α-satellite higher-order repeats (HORs), human centromere sequences have long resisted detailed genomic analysis. Although the development of long-read sequencing platforms has enabled the analysis of complete centromere sequences, their application to a large set of samples is still largely limited, preventing our understanding of centromere variation and haplotype structures across large human populations and the structural basis of centromere-involving translocations in cancer. Here we show that rare k-mers present in centromeric regions can serve as effective markers for dissecting the complexity of centromere structure, particularly that of active α-satellite HOR arrays (aHOR arrays), across human populations and for understanding centromere-involving abnormalities in cancer. Based on rare k-mer-based clustering, centromere aHOR arrays are clustered into discrete haplogroups (aHOR-HGs) with distinct structural features. These k-mers were also used to develop a framework that enables the inference of haplogroups in a given sample based on short-read whole genome sequencing (WGS) data (ascairn). By applying ascairn to large-scale human population datasets ( n > 3,300), we revealed the diversity of aHOR-HGs and their geographic histories across populations. The rare k-mer-based approach was also applied to investigate the structure of 1p/19q co-deletion, a highly recurrent centromere-involving translocation in IDH -mutated oligodendrogliomas. Analyzing short-read WGS data from 142 cases with 1p/19q co-deletion using rare k-mers, we showed that breakpoints of 1p/19q co-deletion were mapped to aHOR arrays in chromosomes 1 ( D1Z7 ) and 19 ( D19Z3 ), which was validated by long-read sequencing of two 1p/19q co-deletion-positive cases. Notably, the translocation preferentially involved haplogroups composed of haplotypes containing larger regions susceptible to rearrangement. These results highlight the role of rare k-mers in dissecting the complexity of centromere sequences and their evolutionary history as well as understanding centromere-involving abnormalities associated with human diseases.
Year:
2025
Oculopharyngodistal myopathy (OPDM) is caused by CGG triplet repeat expansions in six genes. To explore the genetics and epigenetics of OPDM, we conducted CRISPR/Cas9-targeted resequencing of repeat regions in 89 patients. Repeat regions essentially comprised pure CGG expansions, but exhibited size variability, even within patients. Expanded LRP12 and GIPC1 alleles showed distinct single nucleotide variant patterns, suggesting founder haplotypes. LRP12 -expanded reads lacked flanking sequences present in non-expanded reads, whereas GIPC1 expanded repeats contained specific nucleotide patterns in their 5’-regions. Structural variations were identified in some patients. A significant inverse correlation was observed between repeat length and age at onset in patients with GIPC1 or NOTCH2NLC expansions, while this was disturbed by higher methylation of expanded regions in patients with LRP12 expansions, leading to delayed onset. These findings reveal a complex interplay among repeat size, sequence context, and epigenetic state in OPDM pathogenesis, advancing knowledge and providing opportunities for therapeutic intervention.
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2022
Collaborators (103)
Kyuto Sonehara
Associate Professor
University of Tsukuba
Qingbo Wang
Associate Professor
University of Tokyo
Annique Claringbould
Assistant Professor
Erasmus MC
Marie Loh
Assistant Professor
Lee Kong Chian School of Medicine
Claire Palles
Associate Professor
University of Birmingham
Javier Martin
Professor
Instituto de Parasitología y Biomedicina López-Neyra
Katie Burnham
University of Oxford
Sini Nagpal
Assistant Professor
Indian Institute of Technology, Bombay
Brenda WJH Penninx
Professor
-
Yotaro Ochi
Kyoto University
René Pool
University of Amsterdam
Markus Scholz
Leipzig University
Ines Gockel
University Hospital Leipzig
Johannes Schumacher
Philipps-Universität Marburg
Farzana Jasmine
Staff Scientist
University of Chicago
Sergio E Baranzini
Professor
University of California
Yoshitaka Isaka
Osaka University Graduate School of Medicine
Tsubasa Miyauchi
Keio University Hospital
Marta Eugenia Alarcón Riquelme
Scientific Director
Centro Pfizer - Universidad de Granada - Junta de Andalucía de Genómica e Investigación Oncológica
Laura Raffield
Assistant Professor
University of North Carolina at Chapel Hill
Dirk Paul
Interim Head of PMB BioPharma
AstraZeneca UK Limited
Axel Hillmer
Assoc. Prof
University Hospital Bonn
Puya Gharahkhani
Team Head, Associate Professor
QIMR Berghofer Medical Research Institute
Taro Tsujimura
Lecturer
Kyoto University
Yuan Luo
Chief AI Officer and Associate Professor
Northwestern University
Digna R. Velez Edwards
Vanderbilt University Medical Center
Seiya Imoto
University of Tokyo
Masayuki Nishide
Osaka University
Hideyuki Okano
Dean and Professor
Keio University School of Medicine
Yuji Yamamoto
Osaka University Graduate School of Medicine
Erik Garrison
Associate Professor
University of Tennessee Health Science Center
Jouke-Jan Hottenga
Senior Researcher
Hamad Bin Khalifa University
Roel A. Ophoff
Professor
University of California, Los Angeles
Seishi Ogawa
Kyoto University
Atsushi Kumanogoh
Professor
Osaka University Graduate School of Medicine
Ana Viñuela
Academic, Lecturer (Teaching and Research)
University of Dundee
Pashupati Mishra
Tampere University
Emma Elisabeth Davenport
Group Leader
Wellcome Sanger Institute
Lisa Moran
Dietitian
MONASH UNIVERSITY
José Manuel Soria Fernández
Principal Investigator. Head of Group
Hospital de la Santa Creu i Sant Pau
Ian Tomlinson
University of Edinburgh
Julian Knight
University of Oxford
Mika Kähönen
University of Tampere
Muhammad Kibriya
Research Associate Professor
University of Chicago
Alexander Teumer
Professor
University Medicine Greifswald
Keisuke Kataoka
Chief
National Cancer Center Research Institute
Alan Sanders
Clinical Associate Professor of Psychiatry
NorthShore University HealthSystem
Francine Z Marques
MONASH UNIVERSITY
Andrew Brown
Principal Investigator
University of Dundee
Carlo Maj
Head of Bioinformatics | Research Group Leader – Genetic Epidemiology
University of Marburg
Chaoran Yang
Monash University Malaysia.
Toni Boltz
Massachusetts General Hospital
Akiyoshi Nakayama
Professor
National Defense Medical College
Quinn Ostrom
Assistant Professor
Duke University School of Medicine
Zoltán Kutalik
Full Professor
University of Lausanne
Soumya Raychaudhuri
Harvard University
Caleb Lareau
Assistant Member
Memorial Sloan Kettering Cancer Center
David Whiteman
Deputy Director
QIMR Berghofer Medical Research Institute
Beatrice Melin
Professor
Umea University
Katja Pahkala
Associate professor, Academy research fellow
University of Turku
Emma Raitoharju
Senior Researcher
University of Tampere
Stuart MacGregor
Professor
QIMR Berghofer Medical Research Institute
Yasunori Kogure
Senior Researcher
National Cancer Center Research Institute
Dominik Heider
Diretor
University of Münster
Jonathan Shortt
Assistant Research Professor
University of Colorado Anschutz Medical Campus
Grant Montgomery
Professorial Research Fellow
University of Queensland
Annette Peters
Chair of Epidemiology
Ludwig-Maximilians-Universität München
Kaur Alasoo
Associate Professor
University of Tartu
Motohiro Kato
-
Fumitaka Inoue
Associate Professor
Kyoto University
Joachim Thiery
Dean of Medicine and UKSH Board for Research snd Education
Kiel University
Glennis Logsdon
Assistant Professor
University of Pennsylvania
Alexis Battle
Professor
Johns Hopkins University
Ichizo Nishino
Director
-
Holger Kirsten
Leipzig University
Olli T. Raitakari
University of Turku
Alexander Gusev
Associate Professor
Dana-Farber Cancer Institute
Uwe Völker
Professor, Head of Department
Universitätsmedizin Greifswald
Masayuki Mizui
Osaka University Graduate School of Medicine
Steven Reilly
Assistant Professor
Yale University
Jan Veldink
Professor of Neurology and Neurogenetics
University Medical Center Utrecht, Utrecht University
Todd Edwards
Assistant Professor
Vanderbilt University
Suvi Rovio
Adjunct professor, senor researcher
University of Turku
Kit Curtius
Research Health Scientist (PI)
University of California, San Diego
Carlos Cruchaga
Professor
Washington University in St. Louis
Carla van der Kallen
University of Maastricht
Kazuma Sugie
-
Terho Lehtimäki
University of Tampere
Greg Gibson
Regents Professor
Georgia Tech
Shinichi Takahashi
Professor
Keio University School of Medicine
Melissa Bondy
Professor/Department Chair
Stanford University
Marleen van Greevenbroek
University of Maastricht
Benjamin Langmead
Associate Professor
Johns Hopkins University
Janusz Jankowski
Professor
University College London
Richard Gallo
University of California, San Diego
WeiQi Wei
Professor
Vanderbilt University Medical Center
Yun Li
Professor
University of North Carolina
Satoru Morimoto
Project Professor
Keio University School of Medicine
Ryuta Saito
Professor
Nagoya University Graduate School of Medicine
Kazuya Motomura
Chief
Nagoya University Graduate School of Medicine
Yuki Saito
National Cancer Center Research Institute
Dorret I Boomsma
Full professor
University of Amsterdam
Takanori Hasegawa
Associate Professor
Institute of Science Tokyo
Make your next move.
Prepare your application
Review drafts before you send them.